Search results
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
12 paź 2022 · A decade after the U.S. Food and Drug Administration (FDA) did not approve Ampligen (rintatolimod) for the treatment of ME/CFS, this antiviral and immuno-modulator drug is getting a rare second chance.
11 lis 2022 · In October 2022, an immuno-pharma company known as AIM ImmunoTech received approval from the FDA to start its Phase 2 study to evaluate their Investigational New Drug (IND), Ampligen, as a potential treatment for long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
10 lip 2023 · The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
28 lip 2022 · The preliminary data from this uncontrolled clinical trial found that patients reported statistically significant improvements in chronic fatigue after treatment with Ampligen. Based on these early results, AIM is working to move forward with a Phase 2 controlled trial.
12 sie 2022 · AIM ImmunoTech plans to open up multiple sites where physicians can administer infusions of Ampligen, extending beyond the two trial locations in the expanded access study, Equels adds. The expanded access study takes place at sites in Incline Village, Nevada and Charlotte, North Carolina.
29 lut 2024 · AIM’s dsRNA product candidate, Ampligen ® (rintatolimod), is being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at major cancer research centers around the country.
